Soliton Announces Third Quarter 2020 Financial Results and Business Update on Thursday, November 12th, 2020
Soliton, Inc. (Nasdaq: SOLY) will announce its Q3 2020 financial results on November 12, 2020, prior to U.S. market opening. The company will host a conference call at 8:30 a.m. ET to discuss these results, followed by a Q&A session. Soliton is focused on bringing its Rapid Acoustic Pulse (RAP) device to market, currently cleared for tattoo removal. The company aims to enhance affordability and profitability in tattoo removal compared to conventional methods. A replay of the conference call will be available until November 19, 2020.
- Soliton is poised to release its Q3 2020 financial results, indicating ongoing business activity.
- The RAP device aims to lower costs for patients and increase profitability for practitioners.
- No financial metrics or guidance included in the upcoming report, limiting investor insights.
HOUSTON, Oct. 29, 2020 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, announced today that it will report its third quarter 2020 financial results and provide a business update on Thursday, November 12th, 2020 before the open of the U.S. financial markets.
Management will host a conference call and live webcast to discuss Soliton's financial results at 8:30 a.m. ET that same day. A question and answer session will follow management remarks.
The dial-in numbers for the conference call are (833) 423- 0479 for domestic callers and (918) 922-2373 for international callers. The conference ID is 3493411.
A replay of the call will be available following its completion through November 19th, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 3493411.
A live audio webcast of the call and an updated investor presentation will be available on the Investor Relations page of the Soliton, Inc. website, https://ir.soliton.com/. A replay of the webcast will be archived on Soliton's website for 30 days following the completion of the call.
Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. The Company's first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods. Soliton has filed a 510(k) application with the FDA for clearance of its RAP device to improve the appearance of cellulite and is investigating potential additional capabilities of the RAP technology. The device is currently cleared in the United States only for use in tattoo removal and is not yet cleared for use to address cellulite.
For more information about the Company, please visit: http://www.soliton.com
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which statements involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results or outcomes may prove to be materially different from the expectations expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would," ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed in our filings with the Securities and Exchange Commission ("SEC"), including under the heading " Risk Factors" in the Form 10-K for year ended December 31, 2019 filed with the SEC and as updated in our Form 10-Q filings and in our other filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
View original content to download multimedia:http://www.prnewswire.com/news-releases/soliton-announces-third-quarter-2020-financial-results-and-business-update-on-thursday-november-12th-2020-301162673.html
SOURCE Soliton, Inc.
FAQ
When will Soliton report its Q3 2020 financial results?
What time is the Soliton conference call?
What is the Rapid Acoustic Pulse device?
How can I access the replay of Soliton's conference call?
What are the potential applications of Soliton's technology?
